# Diabetes Research Hub — Monitor Review Report
**Run date:** 2026-07-03
**Previous run:** 2026-07-02
**Mode:** Automated review (no files modified)

---

## Executive Summary

Pipeline is healthy — all four data feeds refreshed on schedule (trials + PubMed at 02:05–02:06, monitor at 02:10). Since yesterday: **4 new trials, 1 removed, 2 status changes, 37 new / 38 dropped PubMed papers, 6 new cross-domain papers.** No new trial results posted in the 7/2→7/3 window.

The single most actionable external event: **FDA expanded teplizumab (Tzield) to newly-diagnosed pediatric Stage 3 T1D in June 2026** — and this is corroborated by two fresh PubMed papers in the feed. Worth a tracker update. The gap data is now 3 days old (generated 6/30); still inside tolerance but flag if it slips past 6/30 + 14d.

---

## File System Status

| File | Last Modified | Status |
|------|---------------|--------|
| clinical_trials_latest.json | 2026-07-03 02:05 | ✅ Fresh |
| pubmed_recent_latest.json | 2026-07-03 02:06 | ✅ Fresh |
| hub_monitor_report.md | 2026-07-03 02:10 | ✅ Fresh |
| literature_gap_report.md | 2026-07-02 03:10 | ✅ Fresh (1d) |
| literature_gap_data.json | 2026-06-30 02:13 | ⚠️ 3 days old |

Snapshots present and continuous through 2026-07-03 for both trials and PubMed. Hub monitor flags **771 result files >14 days old** and **985 unchanged of 1004 tracked** — expected for an accreting archive, not a problem. No files missing; no scripts need to be re-run to populate the workspace.

---

## Clinical Trial Changes (7/2 → 7/3)

**Snapshot diff:** 4 new trials, 1 removed, 2 status changes, 0 new results posted.

Status changes:
- **NCT07158970** — Home-Ultrasound in High-Risk Gestational Diabetes: `NOT_YET_RECRUITING → RECRUITING`
- **NCT07039942** — French Prospective Multicentric real-world study: `RECRUITING → ACTIVE_NOT_RECRUITING`

**Trial base:** 839 total (152 T1D cure/cell therapy, 74 T1D immunotherapy, 147 T2D novel, 230 device, 310 recently-completed-with-results). **48 Phase 3 trials are actively RECRUITING.**

### Key Phase 3 / sponsor watch

**Vertex (zimislecel / VX-880 islet cell therapy)** — 2 Phase 3 trials still RECRUITING (NCT06832410, NCT04786262); VX-264 (NCT05791201) is Phase 1/2 active-not-recruiting. No status change this cycle. [Context — Likely] Vertex has publicly pulled its FDA submission target forward to 2026; nothing in the trial feed reflects a filing yet, so this remains a watch item, not an event.

**Eli Lilly** — 31 trials tracked. Phase 3 recruiting includes **baricitinib in T1D beta-cell preservation** (NCT07222332, NCT07222137) and **dulaglutide pediatric** (NCT06739122). Orforglipron Phase 3 program is broad but mostly active-not-recruiting/completed (NCT06010004 long-term safety **posted results 2026-06-30**).

**Novo Nordisk** — 29 trials. Phase 3 recruiting: **insulin icodec** (NCT07076199) and **CagriSema** (NCT07564414). NCT06340854 (basal-insulin switch) **posted results 2026-07-02**.

**Sana Biotechnology** — 0 trials matched in current snapshot. [Guessing] Either not captured under this sponsor string or none active; worth a manual ClinicalTrials.gov check if Sana is a priority to track.

### Recently posted results worth a look (last ~14 days)
- **2026-07-02** NCT06340854 (Novo, basal→icodec switch); NCT04724330 (weight-gain-limiting pragmatic RCT); NCT05579743 (remote monitoring)
- **2026-06-30** NCT06010004 (**orforglipron long-term safety**); NCT05756361 (family-based T1D treatment)
- **2026-06-25** NCT07566299 (early GLP-1 + SGLT2 add-on strategy)

---

## PubMed Highlights

160 unique papers over a 30-day lookback across 16 alert domains. 37 new / 38 dropped vs. yesterday.

### Cross-domain papers (highest value — 6 new this cycle, 14 total in feed)
- **[42390946]** Validated proteomic score from the **EXSCEL trial** predicts CV events — *T2D GLP-1 · AI/ML · Biomarker* → directly on our **Tier 1 Multi-Omics + AI/ML** turf.
- **[42388102]** Rebooting blood-vessel repair — SEMA-VR CardioLink-15 trial — *T2D GLP-1 · Remission*
- **[42388875]** Dulaglutide vs empagliflozin add-on — *T2D GLP-1 · Microbiome*
- **[42389273]** Omega-3 PUFAs, microbiota & M2 macrophages in T1D — *T1D Stem Cell · Microbiome*
- **[42393152]** Dual-branch fundus deep-learning for ocular disease — *AI/ML · Complications*
- **[42387310]** Intensifying once-weekly **insulin icodec** + semaglutide — *T2D GLP-1 · Key Therapy: icodec*

### Key-therapy mentions
Feed matched papers for orforglipron (5), retatrutide (5), CagriSema (5), baricitinib (4), teplizumab (5), icodec (5), dapagliflozin (5). **zimislecel: 0** — no new literature this cycle.

Two teplizumab papers stand out and tie to breaking news below:
- **[42295172]** "An expanded indication for teplizumab (Tzield)"
- **[42332392]** "Teplizumab (Tzield) for the delay of type 1 diabetes"

Volume looks steady across domains; no anomalous spikes or dropouts this cycle.

---

## Gap Analysis Summary

From `literature_gap_report.md` (generated 6/30, 435 pairs, BRONZE validation — single analytical source, needs expert confirmation per Doctrine).

Top under-researched intersections (Gap Score 100, plausible mechanism):
1. **Beta Cell Regen × Health Equity** (0 joint) — who gets access to regenerative therapies
2. **Insulin Resistance × Islet Transplant** (1) — IR affects graft survival
3. **Islet Transplant × Drug Repurposing** (0) — repurpose immunosuppressants for islet protection
4. **Islet Transplant × Health Equity** (0) — access at select centers only
5. **Gene Therapy × LADA** (0) — LADA autoimmune mechanism as gene-therapy candidate

**Alignment with our Tier 1 areas:** #3 (Islet Transplant × Drug Repurposing) and the cluster of Drug-Repurposing pairs (× Health Equity, × LADA, × Glucokinase) map straight onto **Tier 1 #4 (Drug Repurposing Computational Screening)** — highest actionable overlap. The EXSCEL proteomic-score paper above reinforces **Tier 1 #1 (Multi-Omics)** and **#5 (AI/ML)**. These are the intersections where the hub has both data access and a real gap to fill.

---

## Breaking News (web check, last ~7 days)

- **[Certain] FDA expanded teplizumab (Tzield) to newly-diagnosed Stage 3 pediatric T1D (ages 8–17), June 2026** — accelerated approval; first disease-modifying option in that population. Directly corroborated by two papers now in the PubMed feed. **This is the actionable item of the cycle.**
- **[Certain] Dexcom Stelo cleared OTC for pediatric use (ages 2+, non-insulin), June 12 2026** — first OTC CGM for a pediatric population. Relevant to the Diabetes Technology / CGM tracking domain.
- **[Likely] Retatrutide** showed strong T2D + weight-loss data at ADA 85th Scientific Sessions (June 2026) — consistent with our retatrutide Phase 3 tracking; watch for trial-status/results changes.
- **[Likely] Vertex zimislecel** — FDA submission timeline pulled forward to 2026 (fast-track); potential availability ~2027. No filing reflected in trial feed yet.

---

## Recommended Actions

1. **Update tracker: teplizumab pediatric expansion.** Log the June 2026 FDA expanded indication against the T1D Immunotherapy domain and link PMIDs 42295172 + 42332392. Evidence level: regulatory action + secondary literature (not primary trial data) — mark accordingly per Doctrine.
2. **Review cross-domain paper [42390946]** (EXSCEL proteomic CV-risk score) — highest-value hit; sits on Tier 1 Multi-Omics/AI-ML. Candidate for deeper synthesis.
3. **Manual check on Sana Biotechnology** — 0 trials matched; confirm whether that's a sponsor-string miss or genuinely no active trials before trusting the zero.
4. **Refresh gap analysis after 2026-07-14** — `literature_gap_data.json` is 3 days old now; re-run `python project1_literature_gap_analysis.py` if it crosses the 14-day line.
5. **No script re-runs needed** — all four feeds are current. Pipeline nominal.

---

*Generated by the Diabetes Research Hub automated monitor. Review-only run — no source files modified. Gap classifications are BRONZE (single-source) pending expert validation per Research Doctrine v1.0.*
